Plain-English translation of NCT06496490 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called TQB2102 for people with advanced lung cancer that cannot be treated with surgery or radiation and has stopped responding to standard therapies. TQB2102 is an antibody-drug combination designed to find and kill cancer cells that have a specific genetic change (HER2). Some participants will receive the medication alone, while others will receive it combined with another drug to see which approach works best.
Many people with advanced lung cancer run out of effective treatment options after standard therapies stop working. This medication was designed to target a specific genetic change in cancer cells, potentially offering hope for patients who have limited alternatives.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the medication every 3 weeks, with each treatment cycle lasting 21 days. Depending on which group you are assigned to, you may receive the medication alone or combined with another drug. You will need to attend regular clinic visits for infusions, blood tests, and imaging scans to monitor how well the treatment is working and to watch for side effects. The trial involves 270 participants total, and you would continue treatment as long as it is helping and you are tolerating it well.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China